Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer
Maria J. Martinez(University of Miami), Kerry L. Burnstein(University of Miami), Alex Grunfeld(Sylvester Comprehensive Cancer Center), Nahuel Peinetti(University of Miami), Rolando Lyles(University of Miami)
Cited by 14
Related Papers
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
|Pharmacological Reviews|2006|430
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
|European Urology|2017|130
Inefficient N2-Like Neutrophils Are Promoted by Androgens During Infection
|Frontiers in Immunology|2018|69
Nuclear Targeting of Cyclin-Dependent Kinase 2 Reveals Essential Roles of Cyclin-Dependent Kinase 2 Localization and Cyclin E in Vitamin D-Mediated Growth Inhibition
|Endocrinology|2010|63
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023
|Pharmacological Reviews|2023|47